Strides Pharma Q1FY27 Revenue Up 13% YoY to ₹12,654m

Strides Pharma Science Ltd reported a steady performance for Q1FY27, with revenue growing 13% year-on-year to ₹12,654 million. The Ex-US markets showed robust growth of 17% YoY, contributing ₹5,875 million, while the US business remained steady at ₹6,282 million, up 4% YoY. EBITDA increased by 5.4% YoY to ₹2,298 million, despite a ₹131 million impact from geopolitical disruptions on freight and operating costs. Operational PAT grew 8% YoY to ₹1,231 million. The company also unlocked ₹1,000 million in value through the divestment of its majority stake in Pivot Path, its captive GCC, while retaining meaningful participation. Net debt was reduced by ₹119 million, with Net Debt-to-EBITDA at 1.52x.